Share Price:

APNASPENAspen Pharmacare Hldgs13900-163 (-1.16%)

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

Aspen partners with Reach for a Dream to bring joy to children with rare diseases 

Turning Dreams into Reality with Reach for A Dream

Aspen launches its 2025 Integrated Report and retains Level 4 B-BBEE status

We’re proud to announce the release of our 2025 Integrated Report and Supplementary Documents, showcasing how Aspen continues to deliver on its purpose — improving the health and quality of life of patients while creating sustainable value for our stakeholders.

Aspen recognised for EY Excellence in Integrated Reporting Award

In September, Aspen once again earned recognition in Integrated Reporting – after receiving the EY Excellence in Integrated Reporting Award.

FY2026 Interim Results Booklet

View or Download

FY2026 Interim Results Short Form Announcement

View or Download

H1 2025 Interim Results Booklet

View or Download

H1 2025 Interim Results Presentation

View or Download

Stakeholder Notes – 23 April 2025

View or Download

Closed Period

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.

Corporate

Our career opportunities are across the corporate spectrum, including Human Capital, Digital Technology, Legal, and Risk & Sustainability. Our employees are given the opportunity to hone their skills and develop the experience of excellence in their chosen field in the pharmaceutical industry.

View our teams below: